Home › Compare › TGIFF vs JNJ

TGIFF vs JNJ: Dividend Comparison 2026

TGIFF yields 40000.00% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TGIFF wins by $5.18024517379999e+22M in total portfolio value
10 years
TGIFF
TGIFF
● Live price
40000.00%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.18024517379999e+22M
Annual income
$51,548,940,318,215,365,000,000,000,000.00
Full TGIFF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — TGIFF vs JNJ

📍 TGIFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTGIFFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TGIFF + JNJ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
TGIFF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TGIFF
Annual income on $10K today (after 15% tax)
$3,400,000.00/yr
After 10yr DRIP, annual income (after tax)
$43,816,599,270,483,060,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, TGIFF beats the other by $43,816,599,270,483,060,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TGIFF + JNJ for your $10,000?

TGIFF: 50%JNJ: 50%
100% JNJ50/50100% TGIFF
Portfolio after 10yr
$2.590122586899995e+22M
Annual income
$25,774,470,159,107,683,000,000,000,000.00/yr
Blended yield
99.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

TGIFF
No analyst data
Altman Z
-7.4
Piotroski
6/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TGIFF buys
0
JNJ buys
0
No recent congressional trades found for TGIFF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTGIFFJNJ
Forward yield40000.00% ✓2.13%
Annual dividend / share$2.00$5.20 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28% ✓
Portfolio after 10y$5.18024517379999e+22M$30.3K ✓
Annual income after 10y$51,548,940,318,215,365,000,000,000,000.00 ✓$4,689.40
Total dividends collected$5.178579568047658e+22M$15.4K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TGIFF vs JNJ ($10,000, DRIP)

YearTGIFF PortfolioTGIFF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$4,010,700$4,000,000.00$10,592$272.30+$4.00M → TGIFF
2$1,503,618,552$1,499,327,102.80$11,289$357.73+$1503.61M → TGIFF
3$526,936,342,129$525,327,470,278.19$12,123$472.89+$526936.33M → TGIFF
4$172,618,628,820,566$172,054,806,934,488.28$13,141$629.86+$172618628.81M → TGIFF
5$52,860,672,107,805,460$52,675,970,174,967,450.00$14,408$846.81+$52860672107.79M → TGIFF
6$15,132,132,379,588,594,000$15,075,571,460,433,242,000.00$16,021$1,151.60+$15132132379588.58M → TGIFF
7$4,049,462,878,006,525,600,000$4,033,271,496,360,366,000,000.00$18,122$1,588.22+$4049462878006525.50M → TGIFF
8$1,013,053,710,099,385,500,000,000$1,008,720,784,819,918,400,000,000.00$20,930$2,228.20+$1013053710099385472.00M → TGIFF
9$236,926,560,546,299,530,000,000,000$235,842,593,076,493,200,000,000,000.00$24,792$3,191.91+$236926560546299510784.00M → TGIFF
10$51,802,451,737,999,890,000,000,000,000$51,548,940,318,215,365,000,000,000,000.00$30,274$4,689.40+$5.18024517379999e+22M → TGIFF

TGIFF vs JNJ: Complete Analysis 2026

TGIFF — Stock

1933 Industries Inc., a cannabis company, engages in the cultivation and production of medical marijuana in the United States and Canada. It operates in the medical and recreational cannabis sectors. The company also offers cannabidiol (CBD) infused products, such as vape pens, cartridges, lotions, lip balms, hemp seed oils, edible products, topical and dietary supplements, cosmetics, tinctures, sauces, vaporizers, drink additives, baking items, sweeteners, capsules, and tetrahydrocannabinol concentrates under the Canna Hemp, Canna Hemp X, Canna Hemp PLUS, Canna Hemp HEMP, and Canna Fused brands. In addition, it provides cannabis flowers and concentrates. 1933 Industries Inc. offers CBD infused products through retail dispensaries, retail outlets, and e-commerce platform. The company was formerly known as Friday Night Inc. and changed its name to 1933 Industries Inc. in September 2018. The company is headquartered in Vancouver, Canada.

Full TGIFF Calculator →

JNJ — Healthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this TGIFF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TGIFF vs SCHDTGIFF vs JEPITGIFF vs OTGIFF vs KOTGIFF vs MAINTGIFF vs ABBVTGIFF vs MRKTGIFF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.